XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Oct. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Feb. 28, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2023
USD ($)
Item
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
USD ($)
License And Collaboration Agreements [Line Items]                                  
Revenue recognized related to upfront and milestone payments                             $ 1,369,000    
Revenue recognized related to upfront and milestone payments                           $ 18,586,000      
Licenses revenue                           306,911,000 369,193,000 $ 583,187,000  
Deferred revenue                           4,850,000 15,346,000 16,709,000  
Product Revenue, Net                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           $ 285,299,000 366,511,000 $ 580,320,000  
Mochida Pharmaceutical Co., Ltd. | In-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Milestones payment         $ 1,000,000 $ 1,000,000 $ 1,000,000                    
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                                  
License And Collaboration Agreements [Line Items]                                  
Upfront payment                                 $ 2,700,000
Edding | Out-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable up-front received                         $ 15,000,000        
Number of indications of the regulatory milestone events relating to the submission and approval | Item                           3      
Amounts to be received upon achievement of the regulatory milestone events                           $ 25,000,000      
Sales-based milestone event payment                           120,000,000      
Milestone payments received                           9,000,000      
Revenue recognized related to upfront and milestone payments                           12,900,000 600,000    
Deferred revenue                           4,400,000 9,300,000    
Edding | Out-licenses | Licensing Revenue                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           20,600,000 7,700,000    
Edding | Out-licenses | Product Revenue, Net                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           1,800,000 200,000    
Edding | Out-licenses | Maximum                                  
License And Collaboration Agreements [Line Items]                                  
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                           145,000,000      
Amounts to be received upon achievement of the regulatory milestone events                           15,000,000      
Sales-based milestone event payment                           50,000,000      
Edding | Out-licenses | Minimum                                  
License And Collaboration Agreements [Line Items]                                  
Amounts to be received upon achievement of the regulatory milestone events                           2,000,000      
Sales-based milestone event payment                           5,000,000      
Edding | Out-licenses | Clinical Trial Application                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received                       $ 1,000,000          
Edding | Out-licenses | Achievement of REDUCE-IT Trial                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received $ 3,000,000                                
Edding | Out-licenses | MARINE                                  
License And Collaboration Agreements [Line Items]                                  
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                           3,900,000      
Additional license revenues                           5,000,000      
Reduction in net loss                           5,000,000      
Remaining performance period amount                           1,100,000      
Edding | Out-licenses | MARINE | VASCEPA                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received     $ 5,000,000                     $ 5,000,000      
Edding | Out-licenses | MARINE | Maximum                                  
License And Collaboration Agreements [Line Items]                                  
Revenue recognition period of non-refundable up-front payment                           3 years      
Edding | Out-licenses | MARINE | Minimum                                  
License And Collaboration Agreements [Line Items]                                  
Revenue recognition period of non-refundable up-front payment                           11 years      
Biologix FZCo                                  
License And Collaboration Agreements [Line Items]                                  
Revenue recognition period of non-refundable up-front payment                           8 years      
Biologix FZCo | Out-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received                           $ 5,300,000      
Reduction in net loss                           5,300,000      
Revenue recognition period of non-refundable up-front payment                       10 years          
Biologix FZCo | Out-licenses | Product Revenue, Net                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           3,400,000 1,000,000    
HLS | Out-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable up-front received                     $ 5,000,000            
Non-refundable milestone payment received               $ 2,500,000 $ 3,800,000 $ 2,500,000              
Revenue recognized related to upfront and milestone payments                           5,600,000 700,000    
Non-refundable milestone payment received                     $ 3,800,000            
Deferred revenue                             5,600,000    
Non-refundable up-front received period                     6 months            
HLS | Out-licenses | Health Canada                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received                     $ 2,500,000            
HLS | Out-licenses | Licensing Revenue                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           13,700,000 8,200,000    
HLS | Out-licenses | Product Revenue, Net                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           3,100,000 $ 2,900,000    
HLS | Out-licenses | Maximum                                  
License And Collaboration Agreements [Line Items]                                  
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                     50,000,000            
HLS | Out-licenses | Achievement of REDUCE-IT Trial                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable milestone payment received                     $ 2,500,000            
CSL Seqirus | Out-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable up-front received       $ 500,000                          
Licenses revenue                           500,000      
Upfront payment receivable       500,000                          
Event-related milestone payments receivable       8,000,000                          
Additional product-related milestone payments receivable       $ 4,000,000                          
Lotus Pharmaceuticals | VAZKEPA                                  
License And Collaboration Agreements [Line Items]                                  
Non-refundable up-front received   $ 300,000                              
Upfront payment receivable   $ 300,000                              
Lotus Pharmaceuticals | Out-licenses                                  
License And Collaboration Agreements [Line Items]                                  
Licenses revenue                           $ 300,000